Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset

Ki vehet részt

• Men and women aged 18 years and over
• Acute ischemic stroke symptom onset between 4.5 to 24 hours prior to enrolment, including wake-up stroke and unwitnessed stroke, onset time refers to "last-seen normal time"
• Pre-stroke modified Rankin scale (mRS) score≤1
• Internal carotid artery, middle cerebral artery M1 or M2 occlusion confirmed by CT/MRI, internal carotid artery, middle cerebral artery M1 or M2 being responsible for signs and symptoms of acute ischemic stroke
• Neuroimaging: target mismatch profile on CT or MRI perfusion: ischemic core volume <70 mL, mismatch ratio≥1.8 and mismatch volume≥15 mL
• Alberta Stroke Program Early CT score (ASPECTS) > 6
• Baseline National Institutes of Health Stroke Scale (NIHSS) 6-25 (inclusive)
• The patient is not planned or cannot undergo thrombectomy or intravenous thrombolysis in accordance with the current version of the Clinical Guidelines
• Written informed consent from patients or their legally authorized representatives

Ki nem vehet részt

• Surgery on the brain or spinal cord in the last 2 months
• Previous stroke or severe traumatic brain injury within 3 months
• Taking new oral anticoagulants in the previous 48 hours with a thrombin time value above normal and the impossibility of administering the specific antagonist idarucizumab (for dabigatran) or the presence of anti-Xa activity (for rivaroxaban, apixaban and edoxaban)
• Acute ischemic stroke within 4,5 h after symptom onset
• Known hypersensitivity to the non-immunogenic staphylokinase
• Convulsive seizures at the onset of the disease, if there is no certainty that the seizure is a clinical manifestation of acute ischemic stroke
• Neuroimaging (CT, MRI) signs of intracranial hemorrhage, brain tumor, arteriovenous malformation, brain abscess, cerebral aneurysm
• Subarachnoid hemorrhage
• Major bleeding currently or within the past 6 months
• Gastrointestinal or genitourinary bleeding in the last 3 weeks. Confirmed exacerbations of gastric ulcer and duodenal ulcer in the last 3 months
• History of hemorrhagic stroke or stroke of unspecified genesis
• Severe liver disease, including liver failure, liver cirrhosis, portal hypertension (with esophageal varices), active hepatitis
• Cancer with an increased risk of bleeding
• Hemorrhagic diathesis, including renal and hepatic failure
• Data on bleeding or acute trauma (fracture) at the time of examination
• Blood glucose <2.8 or >22.2 mmol/L (after blood glucose level correction to the specified values, inclusion of the patient in the study is possible)
• Platelet count below 100,000/mm3
• Concomitant use of indirect oral anticoagulants (warfarin) with INR > 1.7
• Taking direct anticoagulants (heparin, heparinoids) in the previous 48 hours with an APTT value above normal
• Intended to proceed to endovascular treatment
• Persistent blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg), and the inability to reduce systolic blood pressure below 180 mmHg or diastolic blood pressure below 105 mmHg
• Punctures of non-compressible arteries and veins in the last 7 days
• Unable to perform CT or MRI
• Multiple arterial occlusion (bilateral MCA occlusion, MCA occlusion accompanied with basilar occlusion)
• Acute pancreatitis
• Bacterial endocarditis, pericarditis
• Arterial aneurysms, malformations of arteries and veins. Suspected dissecting aortic aneurysm
• Major surgeries or severe injuries within the last 14 days, minor surgeries or invasive procedures within the last 10 days
• Prolonged or traumatic cardiopulmonary resuscitation (more than 2 minutes)
• Pregnant women, nursing mothers, or reluctant to use effective contraceptive measures during the period of trial